Chandana A. Reddy

Chandana A. Reddy

Auto-generated profile, based on publicly available information

Chandana A. Reddy

Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in European Urology
Verified
Journal Article
Closed access
JEJonathan I. Epstein
Jonathan I. Epstein
MZMichael J. Zelefsky
Michael J. Zelefsky
DSDaniel D. Sjoberg
Daniel D. Sjoberg
JNJoel B. Nelson
Joel B. Nelson
LELars Egevad
Lars Egevad
EKEric A. Klein
Eric A. Klein

1 January 2004 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PKPatrick A Kupelian
Patrick A Kupelian
LPLouis Potters
Louis Potters
DKDeepak Khuntia
Deepak Khuntia
JCJay P Ciezki
Jay P Ciezki
CRChandana A Reddy
Chandana A Reddy
EKEric A Klein
Eric A Klein

1 August 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
PKPatrick A. Kupelian
Patrick A. Kupelian
TWTwyla R. Willoughby
Twyla R. Willoughby
CRChandana A. Reddy
Chandana A. Reddy
EKEric A. Klein
Eric A. Klein
AMArul Mahadevan
Arul Mahadevan

6 March 2018 in JAMA
Verified
Journal Article
Open access
PDF file
Amar U. KishanAmar U. Kishan
Amar U. Kishan
RCRyan R. Cook
Ryan R. Cook
JCJay P. Ciezki
Jay P. Ciezki
ARAshley E. Ross
Ashley E. Ross
MPMark M. Pomerantz
Mark M. Pomerantz
CKChristopher R. King
Christopher R. King
Definitive radiotherapy with androgen deprivation therapy and radical prostatectomy are standard treatment options for patients with high-risk prostate cancer, characterized by initial prostate-specific antigen levels greater than 20 ng/mL, biopsy Gleason score 8-10 disease, or lesions with clinical T stage greater than or equal to 3.1 Radiotherapy options include external beam radiotherapy (EBRT) alone and EBRT with a brachytherapy boost (EBRT+BT), with the latter constituting extreme dose escalation. Although randomized trials suggest a biochemical control benefit to EBRT+BT over EBRT, no differences in clinical outcomes have been established.2-4 Whether radical prostatectomy and radiotherapy (either EBRT or EBRT+BT) offer equivalent outcomes for high-risk prostate cancer remains controversial, with no clear evidence from randomized trials.5-7 Previous comparative retrospective series included patients treated during multiple decades to obtain enough person-years of follow-up to identify sufficient clinical events for valid statistical comparison. Thus, these studies have generally included patients treated with lower doses of radiotherapy8 or insufficient androgen deprivation therapy.9,10 As a result, the relevance of such studies to the contemporary setting is unclear.

15 August 2002 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PKPatrick A. Kupelian
Patrick A. Kupelian
MEMohamed Elshaikh
Mohamed Elshaikh
CRChandana A. Reddy
Chandana A. Reddy
CZCraig Zippe
Craig Zippe
EKEric A. Klein
Eric A. Klein
PURPOSE: To review biochemical relapse-free survival (bRFS) rates after either external-beam radiotherapy (RT) or radical prostatectomy (RP) for localized prostate cancer. PATIENTS AND METHODS: All 1,682 patients had pretreatment prostate-specific antigen (PSA) levels and biopsy Gleason scores (bGS) assigned. No adjuvant therapy was administered after local treatment. RP was the treatment in 1,054 patients (63%) and RT in 628 patients (37%). Median follow-up was 51 months (range, 1 to 134). The median follow-up for RP versus RT patients was 50.5 v 51.0 months. Biochemical relapse was considered detectable PSA levels (> 0.2 ng/mL) in RP patients and three consecutive rising PSA levels in RT patients. The analysis was repeated with a more stringent definition of biochemical control after either RP or RT—namely, reaching and maintaining a PSA level ≤ 0.5 ng/mL—and excluding patients receiving any androgen deprivation (AD). RESULTS: Eight-year bRFS rates for RP versus RT were 72% and 70%, respectively (P = .010). Multivariate analysis indicated T stage (P < .001), pretreatment PSA (P < .001), bGS (P < .001), year of therapy (P < .001), and neoadjuvant AD (P = .019) to be the only independent predictors of relapse. Age (P = .78), race (P = .29), prior transurethral resection of prostate (P = .81), and treatment modality (P = .96) were not independent predictors of treatment failure. Fifty-one percent of RP patients had favorable tumors (T1 to T2A, pretreatment PSA ≤ 10 ng/mL, bGS ≤ 7), compared with only 34% of RT patients (P < .001). Repeat analysis with a stringent definition of biochemical failure and excluding patients receiving AD indicated no impact of treatment modality on outcome. CONCLUSION: Eight-year biochemical failure rates were identical between RT and RP in any subgroup. Outcome is determined mainly by pretreatment PSA levels, bGS, clinical T stage, and, for RT patients, radiation dose.

1 July 2000 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
MCMark A Chidel
Mark A Chidel
JSJohn H Suh
John H Suh
CRChandana A Reddy
Chandana A Reddy
SCSam T Chao
Sam T Chao
MLMelissa F Lundbeck
Melissa F Lundbeck
GBGene H Barnett
Gene H Barnett